Ovarian Cancer

The addition of the investigational drug alisertib to a paclitaxel regimen showed promising activity in patients with recurrent ovarian cancer or advanced breast cancer.

A recent survey demonstrated the common tradeoffs most patients report regarding treatment decisions, highlighting the importance of shared decision making.

Rather than revisiting the ghosts of cancer treatments past, I’m focused on using what I’ve learned in three years of active treatment and maintenance for incurable, metastatic cancer.

This is the first approval of a PARP inhibitor as a first-line maintenance treatment for BRCA-mutant gynecologic cancers.

The Food and Drug Administration (FDA) approved BRACAnalysis CDx to be used to identify patients with advanced ovarian cancer who have germline BRCA mutations and are eligible for first line treatment with Lynparza (olaparib) after responding to platinum-based chemotherapy.

A new program offers counseling, patient education and vetted referrals to patients and their families.

Maintenance treatment with Lynparza (olaparib) after chemotherapy has been found to significantly extend progression-free survival in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation, according to a recent phase 3 study.

A cancer diagnosis can lead to discussions about family health history, as well as a whole new world to learn about.

Patients with ovarian cancer are living longer than ever.

To receive payment for counseling and increase access to services, a new bill has been introduced so that genetic counselors receive payment for counseling Medicare beneficiaries.

Certain cancer treatments can affect the mouth, so dental health should be a lifelong commitment.

The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for Lynparza (olaparib) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

Families with certain genetic mutations face many complex and personal choices, including how and when to share such information with their children. Mom's Genes is here to help.

Here are some tips on coping with the disease that seems to affect us all.

Here are the top 5 CURE stories for October 2018.

The PARP inhibitor Lynparza (olaparib) significantly improved progression-free survival (PFS) as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase 3 SOLO-1 trial presented at the 2018 ESMO Congress.

Actress partners with TESARO to launch national movement to help empower the ovarian cancer community

After receiving a breast cancer diagnosis “out of the blue” in 1996, Sue Friedman would later come to find out she also has a BRCA2 genetic mutation – a discovery that would lead to the creation of an organization for individuals in a similar situation.

Although there is never the perfect time to have a risk-related discussion with a child, one clinical psychologist explains ways in which parents can approach the difficult topic.

To combat the psychological effects from a lymphedema diagnosis, patients need to be equipped with the knowledge and understanding of what the condition is and how it is treated.

One family shares their experience with the discovery of a BRCA mutation, and how they discussed it among one another.

Although individuals may have concerns about enrolling in a study, their involvement may lead to new discoveries.

Eva Moon, a writer, musician and performing artist, discusses her genetic mutation and how it changed the direction of her life.

In this episode of CURE Talks Cancer, we caught up with all three storytellers from the “Our Way Forward: Stories that Illuminate the Ovarian Cancer Experience,” storytelling event hosted through a special engagement with The Moth.

New research indicates that aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil) or naproxen (Aleve) could not only reduce the risk of ovarian cancer, but also improve survival with daily use.

After testing positive for the BRCA mutation, Pulaski has become an advocate and authored a book titled “Mom’s Genes,” which focuses on starting the conversation with children about their family’s health history.

Three storytellers offered their experiences with BRCA mutation at a Basser Center for BRCA event in New York City.

In this special edition of the CURE Talks Cancer podcast, we kick off National Hereditary Breast and Ovarian Cancer Week and Previvor Day.

Although immunotherapy’s use in ovarian cancer lags other cancer types, Matthew Powell, M.D., believes there is still promise for checkpoint blockades in this field, likely in combination with other agents.

Seven years ago, I was diagnosed with Lynch syndrome, a hereditary cancer condition which significantly increases my chances of developing early-onset cancer.